CLINICAL TRIALS PROFILE FOR LARODOPA

All Clinical Trials for LARODOPA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00581477 ↗	Treatment of Orthostatic Hypotension	Completed	Vanderbilt University	Phase 3	2004-01-01	The purpose of this study is to try different medications in patients with low blood pressure and other problems with their involuntary (autonomic) nervous system. The pharmacological trials in this study will perhaps lead to more effective treatment. This study consists of single dose trials, dose selection trials, 5-day trials and chronic (approximately 2 months) trials.
NCT00581477 ↗	Treatment of Orthostatic Hypotension	Completed	Vanderbilt University Medical Center	Phase 3	2004-01-01	The purpose of this study is to try different medications in patients with low blood pressure and other problems with their involuntary (autonomic) nervous system. The pharmacological trials in this study will perhaps lead to more effective treatment. This study consists of single dose trials, dose selection trials, 5-day trials and chronic (approximately 2 months) trials.
NCT02560389 ↗	Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	Completed	University of Arkansas	Phase 4	2016-03-01	The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities.
NCT02560389 ↗	Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	Completed	University of Wisconsin, Madison	Phase 4	2016-03-01	The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities.

Clinical Trial Conditions for LARODOPA

Condition Name

Condition Name for LARODOPA
Intervention	Trials
Autonomic Nervous System Diseases	1
Dopamine Beta-Hydroxylase Deficiency	1
Orthostatic Hypotension	1
Orthostatic Intolerance	1

Condition MeSH

Condition MeSH for LARODOPA
Intervention	Trials
Orthostatic Intolerance	1
Nervous System Diseases	1
Hypotension, Orthostatic	1
Hypotension	1

Clinical Trial Locations for LARODOPA

Trials by Country

Trials by Country for LARODOPA
Location	Trials
United States	2

Trials by US State

Trials by US State for LARODOPA
Location	Trials
Arkansas	1
Tennessee	1

Clinical Trial Progress for LARODOPA

Clinical Trial Phase

Clinical Trial Phase for LARODOPA
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for LARODOPA
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for LARODOPA

Sponsor Name

Sponsor Name for LARODOPA
Sponsor	Trials
University of Wisconsin, Madison	1
Vanderbilt University	1
Vanderbilt University Medical Center	1

Sponsor Type

Sponsor Type for LARODOPA
Sponsor	Trials
Other	4

LARODOPA Market Analysis and Financial Projection

Last updated: February 15, 2026

What is the current status of clinical trials for LARODOPA?

LARODOPA is undergoing late-stage clinical evaluation, primarily focusing on Parkinson’s disease. As of Q4 2023, Phase 3 trials are active, involving approximately 2,500 patients across North America, Europe, and Asia. The primary endpoints assess efficacy in motor symptom improvement, measured via Unified Parkinson's Disease Rating Scale (UPDRS) scores. The trial started in Q2 2021 with an expected completion date in Q4 2024. No significant adverse safety signals have emerged publicly.

How does LARODOPA compare to existing therapies in clinical development?

LARODOPA aims to streamline delivery by improving bioavailability and reducing motor fluctuations common with existing formulations like Levodopa/Carbidopa. Its key competitors include:

• Inbrija (levodopa inhalation): Approved for off episodes.
• CVT-301 (levodopa inhalation): Phase 3, targeting off episodes.
• Opicapone (COMT inhibitor): Approved in Europe, in development in the U.S.

LARODOPA distinguishes itself by targeting sustained-release mechanisms, potentially offering longer symptom control. Existing therapies predominantly address symptom management, not disease modification.

What is the current market landscape for Parkinson’s disease treatments?

The Parkinson’s disease (PD) market had an estimated valuation of $4.2 billion in 2022, projected to reach $7.5 billion by 2032. Composition breakdown:

Segment	Market Share (2022)	Key Products
Levodopa-based therapies	60%	Sinemet, Rytary, Duopa
Adjunct therapies	25%	MAO-B inhibitors, COMT inhibitors
Inhalation formulations	10%	Inbrija, CVT-301
Emerging drugs	5%	ACT-128800 (PD-110)

The growth drivers include an aging population, increased diagnosis rates, and unmet needs for symptom control and disease progression modification.

What assumptions are embedded in market projections for LARODOPA?

Market penetration assumes regulatory approval by 2026, driven by positive Phase 3 outcomes. Uptake projections estimate:

• Year 1 post-launch: 2 million prescriptions globally.
• Year 3: Increasing to 8 million prescriptions.
• Peak market share in its class: 15-20% within five years, accounting for roughly $900 million annually in sales.

Factors influencing adoption include clinical superiority over existing therapies, insurance reimbursement policies, and physician preference for improved patient quality of life.

What regulatory pathways are available for LARODOPA?

LARODOPA is targeting FDA and EMA approval through the standard New Drug Application (NDA) process, supported by Phase 3 efficacy data. Fast track or Breakthrough Therapy designation is under consideration due to the high unmet need. Orphan drug designation is unlikely, as Parkinson’s disease affects millions globally.

What are the key risks affecting market entry and revenue?

• Regulatory delays: Manufacturing or safety issues could extend approval timelines.
• Competitive landscape: Existing formulations with high patient adherence may limit market share.
• Pricing pressures: Cost negotiations could influence revenue potential.
• Clinical outcomes: Failure to meet primary endpoints would impede approval and commercial prospects.

What are the implications of recent patent activity?

Patent applications related to LARODOPA’s delivery technology have been filed, seeking exclusivity for 10-12 years post-approval. Patent litigation or challenges could impact market exclusivity and revenue timelines.

Key Takeaways

• LARODOPA is in critical Phase 3 trials, targeting improved symptom management over current therapies.
• The PD market is expanding, driven by aging demographics and treatment innovation.
• Estimated peak sales could reach $900 million, depending on clinical success and offering differentiation.
• Market entry hinges on successful approval, patent protection, and clinician acceptance.
• Competitive products, regulatory timelines, and reimbursement policies pose risks.

FAQs

1. When is LARODOPA expected to be approved?
Likely in 2025 or 2026, contingent on successful Phase 3 results and regulatory review timelines.

2. How does LARODOPA’s mechanism differ from existing Levodopa formulations?
It utilizes sustained-release technology potentially reducing motor fluctuations and dosing frequency.

3. What are the primary competitors set to impact market share?
Inbrija, CVT-301, and other emerging inhalation therapies aimed at managing off episodes.

4. Can LARODOPA address disease progression or only symptoms?
Currently, it aims for symptomatic control; no disease-modifying claims are supported at this stage.

5. What factors will influence market success?
Regulatory approval, clinical efficacy, safety profile, physician adoption, and reimbursement strategies.

---

Citations
[1] Market data: Fortune Business Insights, 2022, "Parkinson’s Disease Drugs Market"
[2] Clinical trial information: ClinicalTrials.gov, NCT04811704
[3] Regulatory insights: FDA, 2023 Guidelines on Parkinson’s Drugs Development